2 Clarke Drive
Cranbury, NJ 08512
© 2022 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Dr Finn reviews the results from the Leap-002 study which evaluates the use of lenvatinib with pembrolizumab in the front-line setting for patients with advanced hepatocellular carcinoma.
The global, randomized, double-blind, Ph3 LEAP-002 study (NCT03713593) evaluated the efficacy and safety of lenvatinib + pembrolizumab (lenva + pembro) vs lenvatinib (lenva) + placebo as 1L therapy for advanced hepatocellular carcinoma (aHCC).
Finn RS, Kudo M, Merle P et al. Primary Results from the Phase 3 LEAP-002 Study: Lenvatinib plus Pembrolizumab versus Lenvatinib as First-line Therapy for Advanced Hepatocellular Carcinoma Abstract presented at: 2022 European Society of Medical Oncology, September 9-13, 2022; Paris, France & Online. Abstract # LBA34 https://oncologypro.esmo.org/meeting-resources/esmo-congress/primary-results-from-the-phase-iii-leap-002-study-lenvatinib-plus-pembrolizumab-versus-lenvatinib-as-first-line-1l-therapy-for-advanced-hepatoce